- Home
- ATER vs BIVI Comparison
ATER vs BIVI Comparison
Compare ATER & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- BIVI
- Stock Information
- Founded
- ATER 2014
- BIVI 2013
- Country
- ATER United States
- BIVI United States
- Employees
- ATER N/A
- BIVI N/A
- Industry
- ATER Home Furnishings
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- ATER Consumer Discretionary
- BIVI Health Care
- Exchange
- ATER Nasdaq
- BIVI Nasdaq
- Market Cap
- ATER 19.5M
- BIVI 18.8M
- IPO Year
- ATER N/A
- BIVI N/A
- Fundamental
- Price
- ATER $2.14
- BIVI $0.95
- Analyst Decision
- ATER Strong Buy
- BIVI Strong Buy
- Analyst Count
- ATER 1
- BIVI 1
- Target Price
- ATER N/A
- BIVI $30.00
- AVG Volume (30 Days)
- ATER 2.8M
- BIVI 230.4K
- Earning Date
- ATER 05-06-2025
- BIVI 05-13-2025
- Dividend Yield
- ATER N/A
- BIVI N/A
- EPS Growth
- ATER N/A
- BIVI N/A
- EPS
- ATER N/A
- BIVI N/A
- Revenue
- ATER $99,045,000.00
- BIVI N/A
- Revenue This Year
- ATER $5.62
- BIVI N/A
- Revenue Next Year
- ATER $8.63
- BIVI N/A
- P/E Ratio
- ATER N/A
- BIVI N/A
- Revenue Growth
- ATER N/A
- BIVI N/A
- 52 Week Low
- ATER $1.86
- BIVI $0.80
- 52 Week High
- ATER $3.95
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- ATER 47.50
- BIVI 37.09
- Support Level
- ATER $2.09
- BIVI $0.99
- Resistance Level
- ATER $2.56
- BIVI $1.10
- Average True Range (ATR)
- ATER 0.29
- BIVI 0.10
- MACD
- ATER -0.02
- BIVI 0.01
- Stochastic Oscillator
- ATER 5.56
- BIVI 34.07
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operated brands including Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.